Spectroscopy acquisition
Agilent Technologies and A2 Technologies have signed a definitive agreement for Agilent to acquire specific assets of A2 Technologies. The acquisition is reported to include substantially all of A2 Technologies' intellectual property, technology, employees and its spectroscopy product portfolio.
Agilent Technologies and A2 Technologies have signed a definitive agreement for Agilent to acquire specific assets of A2 Technologies. The acquisition is reported to include substantially all of A2 Technologies’ intellectual property, technology, employees and its spectroscopy product portfolio.
“A2 Technologies’ products, technology and people are a great fit with Agilent,” said Mike McMullen, president of the company’s chemical analysis group. “We set out to grow our spectroscopy business, which we acquired this past year when Varian joined us, so we can offer customers an even wider range of the industry’s best solutions. Adding A2 Technologies’ cutting-edge, patented technology and top talent is a major move in this direction.”
A2 Technologies, headquartered in Danbury, Connecticut, USA, focuses on Fourier transform infrared (FT‑IR) technology for lab and field use. The company designs, develops and manufactures FT-IR spectrometers for routine analysis and out-of-lab applications in the petrochemical, environmental, aerospace, art conservation, academia and geosciences markets.
“We are very excited about joining the Agilent team as we believe it will greatly benefit our employees and customers,” said Jon Frattaroli, CEO and co-founder of A2 Technologies. “For A2 Technologies, it will mean access to the many resources of Agilent, including their global distribution and support networks, as well as their innovative technology platforms.”
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
